Marker Therapeutics (MRKR) EBITDA (2010 - 2026)

Marker Therapeutics (MRKR) has reported EBITDA for 17 consecutive years, with -$2.6 million the latest figure, recorded in Q2 2026.

• On a quarterly basis, EBITDA rose 48.84% year-over-year to -$2.6 million in Q2 2026; TTM through Jun 2026 was -$10.7 million, a 34.44% increase from a year earlier, with the FY2025 full-year figure at -$12.9 million, down 15.94% from the prior year.
• EBITDA was -$2.6 million for Q2 2026 at Marker Therapeutics, up from -$4.1 million in the prior quarter.
• Over five years, EBITDA peaked at -$1.9 million in Q4 2025 and troughed at -$9.8 million in Q1 2022.
• A 5-year average of -$3.9 million and a median of -$3.5 million in 2023 frame the typical range for EBITDA.
• Across the five-year window, EBITDA jumped 68.88% in 2022 and tumbled 121.93% in 2025, its largest moves.
• Over 5 years, EBITDA stood at -$3.0 million in 2022, then grew by 3.32% to -$2.9 million in 2023, then sank by 31.44% to -$3.9 million in 2024, then jumped by 51.21% to -$1.9 million in 2025, then sank by 39.09% to -$2.6 million in 2026.
• The last three EBITDA figures came in at -$2.6 million (Q2 2026), -$4.1 million (Q1 2026), and -$1.9 million (Q4 2025), per Business Quant data.